Senior Scientist, Bioconjugation & Targeted Nanomedicine
Bristol Myers Squibb
Summary
We are seeking a highly motivated and innovative Senior Scientist to join BMS's Non-Viral Delivery team and advance next-generation targeted nanomedicine, engineering the molecular interfaces that make selective, cell type-specific delivery possible. Embedded within a highly collaborative, multidisciplinary team, you will drive the design, development, and optimization of bioconjugation strategies and targeting ligand architectures that expand what targeted nanoparticles can achieve, unlocking new therapeutic possibilities across challenging cell types and tissues. Working at the interface of chemistry, chemical biology, and nanomedicine, you will help establish the molecular and chemical foundations that translate conjugate design into functional, next-generation delivery systems.
Job description
Position Responsibilities
- Design and develop bioconjugation strategies for targeted nanoparticles across diverse targeting-ligand formats, including antibodies, fragments, and peptides, and nanoparticle surface components.
- Develop and optimize conjugation chemistries and linker strategies across diverse ligand formats to achieve controlled, well-defined conjugates.
- Contribute to targeting ligand engineering, including format selection, conjugation site design, and sequence-level modifications that enable controlled conjugation and functional ligand presentation.
- Develop and apply analytical workflows to characterize bioconjugates to support lead selection and targeted nanoparticle evaluation.
- Develop strategies for integrating targeting ligands into nanoparticle systems and characterize how conjugate design and ligand presentation influence nanoparticle properties and functional delivery.
- Collaborate cross-functionally across protein engineering, formulation and delivery sciences, analytical sciences, immunology, and in vivo pharmacology to translate molecular design into improved targeted nanoparticle architectures and delivery performance.
- Effectively communicate scientific findings and actionable recommendations to multidisciplinary teams and leadership to influence delivery strategy and program decisions.
- Provide scientific mentorship to junior scientists, and contribute to a collaborative, growth-oriented team culture.
Basic Qualifications
- Bachelor's Degree 7+ years of academic and / or industry experience
- Or Master's Degree 5+ years of academic and / or industry experience
- Or Ph.D. or equivalent advanced degree in the Life Sciences 2+ of academic and / or industry experience
Preferred Qualifications
- PhD in Organic Chemistry, Bioengineering, Protein Engineering, Pharmaceutical Sciences, or a related discipline with 2+ years of relevant industry experience; or MS with 5+ years; or BS with 7+ years of relevant experience.
- Strong hands-on expertise in bioconjugation, linker chemistry, and analytical characterization.
- Demonstrated experience with bioconjugation across diverse biomolecular formats, including proteins, antibodies, antibody fragments, and peptides.
- Experience with nanoparticle-based or other complex delivery systems, is desirable.
- Experience with therapeutic conjugate platforms and linker design across modalities, including ADCs, peptide conjugates, or oligonucleotide conjugates, is desirable.
- Hands-on experience with analytical and purification methods for bioconjugate characterization, including LC-MS, HPLC/UPLC, SEC, IEX, HIC, SDS-PAGE, UV/Vis, and AKTA-based chromatography.
- Demonstrated ability to work effectively in multidisciplinary teams and thrive in a highly collaborative, cross-functional research environment.
- Strong scientific communication skills, with the ability to present complex data and mechanistic insights clearly and compellingly to diverse audiences including project teams and senior leadership.
Requirements
- Bachelor's Degree with 7+ years of academic and/or industry experience
- Master's Degree with 5+ years of academic and/or industry experience
- Ph.D. or equivalent advanced degree in the Life Sciences with 2+ years of academic and/or industry experience
- Strong hands-on expertise in bioconjugation, linker chemistry, and analytical characterization
- Demonstrated experience with bioconjugation across diverse biomolecular formats, including proteins, antibodies, antibody fragments, and peptides
- Hands-on experience with analytical and purification methods for bioconjugate characterization, including LC-MS, HPLC/UPLC, SEC, IEX, HIC, SDS-PAGE, UV/Vis, and AKTA-based chromatography
- Demonstrated ability to work effectively in multidisciplinary teams and thrive in a highly collaborative, cross-functional research environment
- Strong scientific communication skills, with the ability to present complex data and mechanistic insights clearly and compellingly to diverse audiences including project teams and senior leadership
Benefits
- Health insurance
- Dental insurance
- Vision insurance
- Life insurance
- Disability insurance
- Retirement benefits
- Flexible time off
- Paid company holidays
- Paid sick leave
- Volunteer days
- Summer hours flexibility
- Parental leave
- Wellbeing support
Company overview
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Founded in 1887 and headquartered in Princeton, New Jersey, the company operates with a unique BioPharma strategy that combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a biotech firm. BMS focuses on transformative therapies in key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and fibrosis. The company has built a sustainable pipeline of potential therapies and leverages translational medicine and data analytics to deliver the right medicine to the right patient at the right time. With over 10,000 employees worldwide, Bristol Myers Squibb maintains a strong commitment to scientific excellence, patient-centric innovation, and global health equity through its foundation. The company's portfolio includes groundbreaking treatments such as Opdivo (nivolumab) for cancer, Eliquis (apixaban) for cardiovascular conditions, and Orencia (abatacept) for autoimmune diseases, among others.